Free tool
FAERS Monitor: Journavx
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219209 or its brand name (Journavx, Suzetrigine). Reports on generic versions are filed under their own applications.
Reports
1,649
Serious
222
13% of reports
Hospitalization
88
Death reported
11
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use249
- pruritus190
- rash147
- paraesthesia111
- nausea104
- dizziness93
- drug ineffective82
- muscle spasms78
- fatigue62
- headache57
- somnolence53
- diarrhoea48
- insomnia48
- hypoaesthesia47
- pain47
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 3 |
| 2022 | 1 |
| 2024 | 2 |
| 2025 | 670 |
| 2026 | 973 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,510 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| paraesthesiaSignal | 111 | 9.0 | 7.5 | 787 |
| pruritusSignal | 190 | 6.3 | 5.5 | 859 |
| muscle spasmsSignal | 78 | 5.4 | 4.4 | 279 |
| rashSignal | 147 | 4.3 | 3.7 | 377 |
| hypoaesthesiaSignal | 47 | 4.0 | 3.0 | 104 |
| off label useSignal | 249 | 3.6 | 3.2 | 492 |
| somnolenceSignal | 53 | 3.4 | 2.6 | 86 |
| dizzinessSignal | 93 | 2.4 | 2.0 | 75 |
| insomniaSignal | 48 | 2.3 | 1.7 | 34 |
| nausea | 104 | 1.7 | 1.4 | 29 |
| headache | 57 | 1.2 | 0.9 | 1 |
| fatigue | 62 | 1.0 | 0.8 | 0 |
| pain | 47 | 1.0 | 0.7 | 0 |
| diarrhoea | 48 | 0.9 | 0.7 | 0 |
| drug ineffective | 82 | 0.8 | 0.6 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.